Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index; 48 of the 126 sources its claims cite were checked for support.
Abstract
Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.
Overview
CoChat Summary
TL;DR
An international ATTD consensus panel recommends standardized continuous glucose monitoring (CGM) time-in-range targets to complement A1C for type 1/type 2 diabetes, older/high-risk individuals, and pregnancy. It defines target TIR, TBR, and TAR cutpoints and cites evidence linking TIR to A1C and diabetes complications.
Key findings
- For type 1/type 2 diabetes, the panel recommends TIR 70–180 mg/dL >70% (>16 h 48 min), TBR <70 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), TAR >180 mg/dL <25% (<6 h), and TAR >250 mg/dL <5% (<1 h 12 min). For older/high-risk individuals, TIR target is >50% (>12 h), TBR <70 mg/dL <1% (<15 min), and TAR >250 mg/dL <10% (<2 h 24 min).
- For pregnancy in type 1 diabetes, the target range is 63–140 mg/dL (3.5–7.8 mmol/L), with TIR >70% (>16 h 48 min), TBR <63 mg/dL <4% (<1 h), TBR <54 mg/dL <1% (<15 min), and TAR >140 mg/dL <25% (<6 h); pregnancy type 2/GDM targets were not included because of limited evidence.
- TIR relates to A1C: TIR 70% and 50% corresponded with A1C approximately 7% (53 mmol/mol) and 8% (64 mmol/mol), respectively; every 10% increase in TIR corresponded to about 0.5% (5.5 mmol/mol) A1C reduction in Beck et al. (n=545 type 1 diabetes) and about 0.8% (8.7 mmol/mol) in Vigersky et al. (n=1,137 type 1/type 2).
- In DCCT data, hazard for retinopathy progression increased by 64% for each 10% reduction in TIR, and microalbuminuria development increased by 40%; in 3,262 people with type 2 diabetes, more advanced diabetic retinopathy was associated with less time in target range. The panel also recommends 14 days of CGM data, >70% CGM active, and %CV target <36% (some studies suggest <33%).
Methods
- Consensus process: in February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes expert in CGM; subgroups reviewed literature and presented evidence-based recommendations to the full panel for voting.
- Data/sample: no new primary trial was conducted; the paper synthesizes cited studies, including Beck et al. (n=545 type 1 diabetes), Vigersky et al. (n=1,137 type 1/type 2), Lu et al. (3,262 type 2 diabetes), DCCT analyses, and pregnancy CGM studies.
- Main analysis: narrative evidence synthesis and expert consensus on CGM metrics, time-in-range cutpoints, and standardized Ambulatory Glucose Profile reporting; no formal meta-analysis or systematic review is described.
Limitations
- The paper states that long-term trials demonstrating how CGM metrics relate to and/or predict clinical outcomes have not been conducted, and the evidence is suggestive; pregnancy percentages are based on limited evidence and more research is needed.
- The paper states there is no evidence regarding time in range for older and/or high-risk individuals, and CGM targets for women with GDM or type 2 diabetes in pregnancy were not included because of lack of evidence.
- Evident from the text: recommendations are consensus/expert opinion rather than a systematic review, and the consensus meeting/manuscript was funded by ATTD with support from multiple industry sponsors; many panel members report industry consulting, speaking, research, or advisory relationships.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
16 Valid · 14 Not valid · 24 Not checked · 13 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] Xing, 2011, Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring, Diabetes Technol Ther sourceExperimental — accuracy not yet measured
In type 1 diabetes, the Results (Table 2; page unavailable) show weaker correlations for hypoglycemia and glycemic variability than for mean glucose at 15 days. But they also show that both correlations increase as sampling extends from 3 to 15 days, contrary to the citing sentence’s claim that an increase with longer sampling has not been shown. The paper does not frame this analysis as >70% CGM use over 14 days. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In individuals with type 1 diabetes, correlations are weaker for hypoglycemia and glycemic variability; however, these correlations have not been shown to increase with longer sampling periods (42).”
What the sources say
- Disputedcites [42] Xing, 2011, Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring, Diabetes Technol Ther sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that correlations with the full three-month data increased as sampling lengthened for both hypoglycemia and glycemic variability. From 3 to 15 days, r² rose from 0.32 to 0.66 for values ≤70 mg/dL and from 0.36 to 0.70 for coefficient of variation—the opposite of the attributed claim. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The first longitudinal CGM data demonstrated a 13percentage point increase in TIR (43% to 56% TIR 70-140 mg/dL [3.9-7.8 mmol/L]) (61).”
What the sources say
- Disputedcites [61] Stewart, 2016, Closed-loop insulin delivery during pregnancy in women with type 1 diabetes, N Engl J Med sourceExperimental — accuracy not yet measured
The Study Outcomes report different CGM time-in-range results: 59.5% to 74.7% overnight and 56.8% to 66.3% over 24 hours with closed-loop therapy. The paper defines its target range as 63–140 mg/dL, not 70–140 mg/dL; it does not report the claimed increase from 43% to 56%. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Numerous studies have demonstrated significant clinical benefits of CGM use in people with diabetes regardless of insulin delivery method (1-15).”
What the sources say
- Not checked — no full text of the sourcecites [1] Lind, 2017, Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial, JAMA source
- Partly supportedcites [2] Aleppo, 2017, REPLACE-BG: A randomized trial comparing continuous glucose monitoring with and without routine blood glucose monitoring in adults with well-controlled type 1 diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
The Introduction reports that several randomized trials found CGM benefits, including reduced HbA1c and hypoglycemia, particularly in adults with type 1 diabetes. But the Conclusions say this trial included only insulin-pump users; extending its results to people using injections is described as reasonable, not demonstrated. The paper therefore does not establish benefits regardless of insulin delivery method or across all people with diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] Beck, 2017, Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial, JAMA source
- Not checked — no full text of the sourcecites [4] Beck, 2017, Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial, Ann Intern Med source
- Not checked — no full text of the sourcecites [5] Polonsky, 2017, The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial, Diabetes Care source
- Supportedcites [6] Šoupal, 2016, Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study, Diabetes Technol Ther source
The Discussion reports significant glycemic benefits from real-time CGM that were comparable with pump (CSII) and injection (MDI) therapy. The study concerns people with type 1 diabetes. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [7] van Beers, 2016, Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial, Lancet Diabetes Endocrinol source
- Not checked — no full text of the sourcecites [8] Bolinder, 2016, Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial, Lancet source
- Partly supportedcites [9] Haak, 2017, Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial, Diabetes Ther sourceExperimental — accuracy not yet measured
The Results report significant reductions in hypoglycemic events with flash glucose monitoring in adults with insulin-treated type 2 diabetes, supporting a clinical benefit. The Results also state that 95% of participants used an insulin pen or syringe and 5% used continuous subcutaneous insulin infusion; the paper does not establish that the benefit held regardless of insulin delivery method. No page numbers are available in our copy. (LLM, conf=0.85)
- Partly supportedcites [10] Choudhary, 2016, Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management, Diabetes Technol Ther sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the CGM-based MiniMed 640G pump system can help patients with type 1 diabetes avoid hypoglycemia. But this short, uncontrolled study examined a predictive pump-suspension system, not CGM use regardless of insulin delivery method; it does not establish a benefit across delivery methods or isolate the benefit of CGM itself. (LLM, conf=0.88)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A1C is currently recognized as the key surrogate marker for the development of longterm diabetes complications in people with type 1 and type 2 diabetes and has been used the primary endpoint for many CGM studies (1; 3; 4; 6; 32; 33).”
What the sources say
- Not checked — no full text of the sourcecites [1] Lind, 2017, Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial, JAMA source
- Not checked — no full text of the sourcecites [3] Beck, 2017, Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial, JAMA source
- Not checked — no full text of the sourcecites [4] Beck, 2017, Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial, Ann Intern Med source
- Could not verifycites [6] Šoupal, 2016, Comparison of different treatment modalities for type 1 diabetes, including sensor-augmented insulin regimens, in 52 weeks of follow-up: a COMISAIR study, Diabetes Technol Ther sourceExperimental — accuracy not yet measured
The Prespecified outcomes section (page unavailable) identifies HbA1c as this type 1 diabetes study’s primary endpoint. Neither that section nor the Discussion passages establish that A1C is the key surrogate marker for long-term complications in people with both type 1 and type 2 diabetes. Searches for that surrogate-marker relationship and for complications found no passage stating it. (LLM, conf=0.72)
- Partly supportedcites [33] Battelino, 2012, The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial, Diabetologia sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) links near-normal glycaemia with reduced complication risk in type 1 diabetes, and Methods > Outcome measure (page unavailable) uses HbA1c as this trial’s primary endpoint. The paper does not establish HbA1c as the key surrogate marker for long-term complications in both type 1 and type 2 diabetes. (LLM, conf=0.81)
- Could not verifycites [32] Novodvorsky, 2017, Diurnal differences in risk of cardiac arrhythmias during spontaneous hypoglycemia in young people with type 1 diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
The Baseline Assessment section says HbA1c was measured at the start of monitoring, but does not describe it as a surrogate marker for long-term complications. The Research Design and Methods section examines arrhythmias during hypoglycemia, not A1C as a primary endpoint in CGM studies. Searches for the surrogate-marker and primary-endpoint claims found no supporting passage in our copy. (LLM, conf=0.76)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 16 with their cited sources checked
Create a free account to see all 67 claims and to verify the 4 references still open.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the advent of newer studies of CGM in noninsulin‐treated individuals and increasing uptake, the utility of CGM is progressively being endorsed in this population.”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycaemia is associated with an increased risk of vascular events, explaining recent consensus advocating hypoglycaemic exposure at <1% (i.e.<15 min/day) in individuals at high CV risk.137,138”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [138]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Considering the older age of participants and comorbid conditions reported, the mean HbA1c, GMI, TIR, and TBR results (8.0%, 7.6%, 56%, and 1.0% at 6 months, respectively) demonstrate close adherence to established glycemic targets (23, 24, 38).”
From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Avaiable data suggest that such systems can increase TIR and reduce hypoglycemia in patients with DGP, with improvements comparable to those observed in individuals without gastrointestinal complications, although data remain limited and largely observational [153–157].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [156]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A subsequent international consensus defined targets for most of the measures on the AGP that would correspond to individualized HbA 1c targets (193).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [193]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ FIGURES / TABLES · p. 4
“2 Figures / 3 Tables”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Time in Ranges · p. 11
“Table 4. Consensus guidance on cutpoints for assessment of glycemic control: Pregnancy”
§ Relationship Between TIR and A1C · p. 15
“Table 4. Estimate of A1C for a given TIR level based on type 1 diabetes and type 2 diabetes studies”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
International consensus on use of continuous glucose monitoring
Danne, T., Nimri, R., Battelino, T., Bergenstal, R. M., Close, K. L., DeVries, J. H., Garg, S., Heinemann, L., Hirsch, I., Amiel, S. A., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1600 · Cited by 2,069
Self-citationState of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
Foster, N. C., Beck, R. W., Miller, K. M., Clements, M. A., Rickels, M. R., DiMeglio, L. A., Maahs, D. M., Tamborlane, W. V., Bergenstal, R., Smith, E., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0384 · Cited by 1,907
Self-citationIsmail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationBeck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 1×
“A1C is currently recognized as the key surrogate marker for the development of long-termdiabetes complications in people with type 1 and type 2 diabetes and has been used as the primary end point for many CGM studies (1,3,4,6,33,34).”
BackgroundSelf-citationBolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Cited by
Items 3,301–3,400 of 3,959
Expanding Use of Continuous Glucose Monitoring in Type 2 Diabetes
Balata, S., Chiang, J., Hassan, A., & Reid, D. J. (2024) · ADCES in Practice · doi:10.1177/2633559x241296156
Hypoglycemia in Pregnant Women with Type 1 Diabetes: Is It Inevitable?
Rosenn, B., Khoury, J. C., Mimouni, F. B., Ehrlich, S. R., & Miodovnik, M. (2024) · American Journal of Perinatology · doi:10.1055/a-2442-7305 · Cited by 1
Coefficient of Variation to Assess the Reproducibility of Meal-Induced Glycemic Responses (Preprint)Preprint
Lubasinski, N., Thabit, H., Nutter, P. W., Petrescu, D., & Haper, S. (2024) · doi:10.2196/preprints.68821
Bilińska, A., Krzesłowska, W., Pernak, B., Wasiak, J., Michalak, A., Pietrzak, I., Mianowska, B., Fendler, W. M., & Szadkowska, A. (2024) · Current Topics in Diabetes · doi:10.5114/ctd/194183 · Cited by 1
Alexanian, S. M., Cheney, M. C., Spartano, N. L., Bello-Ramos, J. C., Reddy, N., Malik, A., Murati, J., Wolpert, H. A., & Steenkamp, D. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.015
Impact of Intensive Insulin Stabilisation Service in Pregnancy with Type 1 Diabetes
Teasdale, S., Cannon, N., Griffin, A., Nisbet, J. C., & McIntyre, D. H. (2024) · Reproductive Medicine · doi:10.3390/reprodmed5040026 · Cited by 1
Zadel, A. H., Chiampas, K., Maktaz, K., Keller, J. G., O'Gara, K. W., Vargas, L., Tzortzakis, A., Eimer, M. J., & Szmuilowicz, E. D. (2024) · doi:10.2196/preprints.69061
Gupta, V., Arora, A., Jindal, A. K., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5186475/v1
Bozzetto, L., Abuqwider, J., Pasolli, E., Scidà, G., Corrado, A., Vitale, M., Filippis, F. D., Ercolini, D., Annuzzi, G., & Rivellese, A. A. (2024) · Research Square · doi:10.21203/rs.3.rs-5541931/v1
AI-Driven Optical Sensing Techniques for Non-Invasive Kidney Function Evaluation
Divya, G., & Vasuki, R. (2024) · International Conference on Power, Energy, Control and Transmission Systems (ICPECTS) · doi:10.1109/icpects62210.2024.10780424
Impacto del inicio de la monitorización flash de glucosa en pacientes adultos con diabetes tipo 1
Sahagún, R. J. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/72390
The Laboratory Diagnosis of Diabetes Mellitus
Bailey, D. N., & Fitzgerald, R. L. (2024) · Springer eBooks · doi:10.1007/978-3-031-67380-1_19
Thomas, L., & Telkar, S. (2024) · Advances in intelligent systems and computing · doi:10.1007/978-981-97-6349-8_36
Technology in the treatment of diabetes
Klouzková, B. (2020) · Journal of Nursing Social Studies Public Health and Rehabilitation · doi:10.32725/jnss.2020.016
李, 康. (2024) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2024.34367
Young, E. C., Alves, S. T. D. F., Borges, M. D. A. P., Furtado, M. S., Ferreira, A. L. D. N., de Figueirêdo, N. M. A., & da Silva, R. C. L. (2025) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.18n.1-005
Delgado, B. R. (2025) · Con-Ciencia Serrana Boletín Científico de la Escuela Preparatoria Ixtlahuaco · doi:10.29057/ixtlahuaco.v7i13.14071
Csermely, A., Borella, N. D., Turazzini, A., Pilati, M., Sheiban, S. S., Bonadonna, R. C., Trevisan, R., Trombetta, M., & Lepore, G. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241308564
佐藤, 淳. (2024) · The Japanese Journal of SURGICAL METABOLISM and NUTRITION · doi:10.11638/jssmn.58.6_185
宗景, 匡. (2024) · The Japanese Journal of SURGICAL METABOLISM and NUTRITION · doi:10.11638/jssmn.58.6_204
新原, 正., & 比企, 直. (2024) · The Japanese Journal of SURGICAL METABOLISM and NUTRITION · doi:10.11638/jssmn.58.6_191
Kaushal, S., Fakembe, P., Halperin, I. J., HAWKER, G. A., & Weisman, A. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.12.005 · Cited by 1
(2000) · Time to knit · doi:10.1016/s1155-1941(23)46691-7
(2000) · Time to knit · doi:10.1016/s1634-6939(23)81612-x
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus Typ 1 im Kindes- und Jugendalter
Holder, M., Kamrath, C., Lange, K., Kummer, S., & Ziegler, R. (2025) · Die Diabetologie · doi:10.1007/s11428-024-01279-6
Automated insulin delivery postpartum: insights from the AiDAPT study extension
O'Neal, D. N., & Ross, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00374-7
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Use of Continuous Glucose Monitoring in Older People with Diabetes
Maltese, G. (2025) · Wiley eBooks · doi:10.1002/9781394205066.ch6
Sinclair, A. J., Abdelhafiz, A. H., Summerbell, A. M., Cukierman‐Yaffe, T., Wylie, S., Muzulu, S., Keegan, G., Mahmoud, S., Athavale, N. V., Emmerton, D., et al. (2025) · Wiley eBooks · doi:10.1002/9781394205066.ch16
Mendes, R. C. M., Albuquerque, N. V., Montenegro, R. M., Martins, M. Y. P. T., Porto, C. M. T. D. S., Nunes, A., Maia, C. S. C., & Araújo, S. T. (2022) · Nutrición clínica y dietética hospitalaria/Nutrición clínica, dietética hospitalaria · doi:10.12873/421machado
Cardona‐Hernandez, R., de la Cuadra-Grande, A., Monje, J., Echave, M., Oyagüez, I., Álvarez, M., & Gea, I. L. (2025) · Journal of health economics and outcomes research · doi:10.36469/jheor.2025.127920 · Cited by 4
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch04
Glycemic Goals and Assessment of Glycemia
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch02
Kurtzig, J., Ferstad, J. O., Dupenloup, P., Zaharieva, D. P., Maahs, D. M., Prahalad, P., Johari, R., Bishop, F. K., Addala, A., & Scheinker, D. (2025) · medRxiv · doi:10.1101/2025.02.03.25321621 · Cited by 1
Suzuki, Y., Miya, A., Nakamura, A., Handa, T., Kameda, H., & Atsumi, T. (2025) · Diabetology International · doi:10.1007/s13340-025-00803-3
Sobczak, M., Pyle, L. L., Sawyer, A., Forlenza, G. P., & Alonso, G. T. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0500 · Cited by 1
Assessing the Accuracy of CGM Metrics: The Role of Missing Data and Imputation StrategiesPreprint
Cichosz, S. L., Kronborg, T., Hangaard, S., Vestergaard, P., & Jensen, M. H. (2025) · medRxiv · doi:10.1101/2025.02.13.25322196 · Cited by 3
Artime, E., Hillman, N., Tinahones, F. J., Pérez, A., Giménez, M., Duque, N., Santos, M. R., Díaz‐Cerezo, S., Redondo‐Antón, J., Spaepen, E., et al. (2025) · Cureus · doi:10.7759/cureus.79134
Dieta mediterrânea e controle glicêmico em crianças e adolescentes com DM1: revisão integrativa
Tucunduva, D. C. D. M., Santana, G. S., Haber, J. F. D. S., Arruda, C. M. D., Detregiachi, C. R. P., Gimenez, F. V. M., & Chagas, E. F. B. (2025) · Caderno Pedagógico · doi:10.54033/cadpedv22n4-166
Continuous Glucose Monitoring for Inpatients on Intravenous Insulin
GOOD, K. L., Joshi, R., & SNELL, V. M. (2025) · Clinical Nurse Specialist · doi:10.1097/nur.0000000000000888
Diabetes mellitus und Schwangerschaft
Laubner, K., & Kleinwechter, H. J. (2025) · Frauenheilkunde up2date · doi:10.1055/a-2385-2307
Flint, K. L., & Toschi, E. (2021) · American Diabetes Association eBooks · doi:10.2337/9781580407663.case30
Continuous Tissue Glucose Monitoring (CGM) and Ambulatory Glucose Profile (AGP)
Schäffler, A., & Karrasch, T. (2024) · Springer eBooks · doi:10.1007/978-3-662-70260-4_36
Highlights of the Most Recent American Diabetes Association Guidelines: From Evidence to Practice
Kim, M. K. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2329
Impact of glucose fluctuations on white matter hyperintensity in type 2 diabetic patients
Chen, X., Qian, W., Wang, X., Yao, J., Ma, Y., & Lian, X. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02471-w
Zoet, S., Urgert, T., Veldhuis, A., van Beijnum, B.-J. F., & Laverman, G. D. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004768 · Cited by 1
Cester, L., Pavan, J., & Favero, S. D. (2024) · IEEE Conference on Decision and Control (CDC) · doi:10.1109/cdc56724.2024.10886510
Keers, L. G., Brodeur, M. R., & Tran, L. (2025) · Journal of Gerontological Nursing · doi:10.3928/00989134-20250212-04
Lilliecreutz, C., Söderström, E., Ersson, M., Bendtsen, M., Brown, V., Kaegi-Braun, N., Linder, R., Maddison, R., Chisalita, S. I., & Löf, M. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-089355 · Cited by 2
Kurtzig, J., Addala, A., Bishop, F. K., Dupenloup, P., Ferstad, J. O., Ramesh Johari, B., Maahs, D. M., Prahalad, P., Zaharieva, D. P., & Scheinker, D. (2025) · doi:10.2196/preprints.72676
Okuno, K., Niihara, M., Fujita, S., Higuchi, T., Harada, H., Washio, M., Sakuraya, M., Kumagai, K., Sato, T., Sangai, T., et al. (2025) · Surgical Case Reports · doi:10.70352/scrj.cr.24-0099
New Insulins, Biosimilars, and Insulin Therapy
Biester, T., & Heinemann, L. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8804.tor
Self-citationDiabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., Prahalad, P., Schweiger, D. Š., & Shalitin, S. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8808.dmm
CGM-Freq: A Python Library for Frequency Domain Analysis of Continuous Glucose Monitoring Data
Healey, E., & Kohane, I. S. (2024) · IEEE-EMBS International Conference on Biomedical and Health Informatics (BHI ...) · doi:10.1109/bhi62660.2024.10913828
WEINZIMER, S. A., & Addala, A. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8812.saw
Self-citationWu, C. C., Wu, K. C., & Reddy, S. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0005
Alqutub, S. T., & Aljehani, F. (2025) · Digital Health · doi:10.1177/20552076251325987 · Cited by 1
Type 1 Diabetes Blood Glucose Management Based on Fuzzy Logic and Reinforcement Learning
Liu, X., Hu, F., Su, Z., & Yang, F. (2024) · International Symposium on Artificial Intelligence and Intelligent Manufacturing (AIIM) · doi:10.1109/aiim64537.2024.10934697
Monnier, L., Colette, C., Renard, É., & Benhamou, P. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2025.03.010
Self-citationClinical Study on the Treatment of Type 2 Diabetes with BMPRP
Liu, B., Dong, Q., Ruping, Z., Gao, X., & Huaiyuan, C. (2025) · Journal of Stem Cell Therapy and Transplantation · doi:10.29328/journal.jsctt.1001048
Recent Advances in Blood Glucose Management for Diabetic Patients Undergoing Hemodialysis
苏, 俊. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.42237
Innovaciones tecnológicas y diabetes
Lablanche, S., Delagenière, J., & Jalbert, M. (2025) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(25)50386-0
Acute Otitis Externa: A Hidden Risk for People With Diabetes
Burroughs, B. T., Stewart, R., & Strelow, B. (2025) · ADCES in Practice · doi:10.1177/2633559x251325832
Ohara, M., Yokoyama, H., Seino, H., Fujikawa, T., Kohata, Y., Takahashi, N., Irie, S., Terasaki, M., Mori, Y., Fukui, T., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01691-y · Cited by 1
A Chrono-nutritional Perspective on Cereal and Snack Research Case Studies
Masutomi, H., Furutani, A., Ueda, S., Shibata, S., & Ishihara, K. (2025) · Nippon Eiyo Shokuryo Gakkaishi · doi:10.4327/jsnfs.78.95
Moderne Technik der Therapieüberwachung bei Diabetes mellitus
Allendorf, I. (2025) · Gefässchirurgie · doi:10.1007/s00772-025-01200-5
Wu, Z., Liu, Z., Zhao, W., Wang, S.-C., Gu, L., & Xiao, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1466358 · Cited by 1
Lee, S. E., Park, J., Kim, D., Lee, H.-A., Kang, Y. S., Yoon, Y.-S., Jeong, Y. J., Choi, H. S., & Kim, K. (2025) · Biomedicines · doi:10.3390/biomedicines13051101
Diagnosis, Therapy and Follow-Up of Type 1 Diabetes Mellitus in Children and Adolescents
Holder, M., Ziegler, R., Kamrath, C., Lange, K., & Kummer, S. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2490-5096
Модель прогнозирования гликемии на основе смешанных временных рядов
Мингалиев, З. З., & Новикова, С. В. (2025) · Herald of Tver State University Series Applied Mathematics · doi:10.26456/vtpmk731
Balatoni, I. (2025) · Children · doi:10.3390/children12050612 · Cited by 1
Endokrine und Stoffwechseldiagnostik
Dietrich, J. W., Schifferdecker, E., Schatz, H., et al. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-60980-4_83
Saito, M., Uchino, H., Fuchigami, A., Sato, G. E., Miyagi, M., & Hirose, T. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70065
Li, Y., Cai, L., Lu, Q., Gong, W., Wang, P., Chen, T., Ye, W., Li, B., Zhu, H., Xu, Z.-F., et al. (2025) · Endocrine · doi:10.1007/s12020-025-04250-7
Friedecky, B. (2020) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2020.031 · Cited by 1
Harmonization of Continuous Glucose Monitoring (CGM)
Friedecky, B., & Kratochvíla, J. (2023) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2023.002
Corbal, B. S., Puzic, R. F. D. S., Leite, E. B., da Silva, É. T., Melo, M. C., Borba, M. D. R., & da Silva, C. M. B. (2025) · Caderno Pedagógico · doi:10.54033/cadpedv22n7-165
Plaitano, E. G., & Stanger, C. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109083 · Cited by 2
Management of Preexisting Diabetes and Gestational Diabetes During Hospitalization
Westcott, G. P., & Brown, F. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-86099-7_26
Nocturnal Glycemic Stability IndexPreprint
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., et al. (2025) · medRxiv · doi:10.1101/2025.05.18.25327867
Weschenfelder, F. (2025) · gynäkologie + geburtshilfe · doi:10.1007/s15013-025-6076-1
Eer, A., Hachem, M., Hearn, T., Koye, D. N., Atkinson‐Briggs, S., Jones, J. L., Eades, S., Braat, S., Twigg, S. M., Sinha, A. K., et al. (2025) · Pilot and Feasibility Studies · doi:10.1186/s40814-025-01607-7
石, 来. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1551562
Bensaid, S., Allix, I., Dubois, S. G., Schaepelynck, P., Verier‐Mine, O., Atlan, C., Sonnet, E., Vambergue, A., Navarranne, A., Borot, S., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112302
Petolicchio, C., Spacco, G., Chiaie, E. D., Calevo, M. G., Minuto, N., Maggi, D. C., Ferone, D., Bassi, M., & Cocchiara, F. (2025) · Endocrines · doi:10.3390/endocrines6020025
Intrapartum continuous glucose monitor metrics and neonatal hypoglycemia
Wilkie, G., Snow, S., Anandakugan, N., et al. (2025) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2025.101712
Andreassen, J., Nikontovic, A., Iversen, E. M., Borðoy, R. Á. F., Rasmussen, P., Petersen, M. S., & Johannesen, H. L. (2025) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2025.05.005
Practical Applications of Wearable Devices for Diagnosis and Monitoring
Kim, H. (2024) · MechEcology · doi:10.23104/me.2024.10.3.2.23
Xu, Q., & Gao, Y. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-09635-y
In silico evaluation of pramlintide dosing algorithms in artificial pancreas systems
Torres, B. P., Sala-Mira, I., Furió-Novejarque, C., Sanz, R., García, P., Díez, J.-L., & Bondía, J. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110447
Polat, G., Düzgün, G., & Avdal, E. Ü. (2025) · İzmir Katip Çelebi Üniversitesi Sağlık Bilimleri Fakültesi Dergisi · doi:10.61399/ikcusbfd.1653358
Medina, A. M. G., Henao, D. C., Múñoz, Ó., Pantoja, Ó. D. L., Cortés, D., Cuervo, A. D. C., Jácome, A., Pertuz, C. M., & Rubio, C. (2025) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514251349342 · Cited by 1
Dimitropoulou, N. M., Eussen, S. J. P. M., Schalkwijk, C. G., & de Galan, B. E. (2025) · Diabetologia · doi:10.1007/s00125-025-06469-5
Zeit im Zielbereich: Welche Werte erreichen Stoffwechselgesunde?
Schmidt, L., & Adamek, H. E. (2025) · Info Diabetologie · doi:10.1007/s15034-025-5124-1
Wang, R., Wu, F., Xue, J., Zhou, Y., Wang, Z., Li, Y., & Bu, L. (2025) · Research Square · doi:10.21203/rs.3.rs-6763811/v1
Krutkyte, G., Banholzer, N., Herzig, D., & Bally, L. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.0248
(2025) · Oxford University Press eBooks · doi:10.1093/med/9780198831846.003.0015
Mizuno, A. N. (2025) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.58.294
O’Brien, K., & Isaacs, D. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_6
Metadata
- Authors
- Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., Cobelli, C., Dassau, E., DeVries, J. H., Donaghue, K. C., Dovc, K., Doyle, F. J., Garg, S., Grunberger, G., Heller, S., Heinemann, L., Hirsch, I. B., Hovorka, R., Jia, W., Kordonouri, O., Kovatchev, B., Kowalski, A., Laffel, L., Levine, B., Mayorov, A., Mathieu, C., Murphy, H. R., Nimri, R., Nørgaard, K., Parkin, C. G., Renard, E., Rodbard, D., Saboo, B., Schatz, D., Stoner, K., Urakami, T., Weinzimer, S. A., & Phillip, M.
- Affiliations
- University of Ljubljana (SI)
- Kinderkrankenhaus auf der Bult (DE)
- Park Nicollet Health Services (US)
- King's College London (GB)
- Jaeb Center for Health Research (US)
- Vita-Salute San Raffaele University (IT)
- Stanford Medicine (US)
- American Diabetes Association (US)
- Close Concerns (United States) (US)
- University of Padua (IT)
- Harvard University (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- The University of Sydney (AU)
- Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children’s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia
- University of Colorado Denver (US)
- Grunberger Diabetes Institute (US)
- University of Sheffield (GB)
- Science Consulting in Diabetes, Neuss, Germany
- University of Washington (US)
- University of Cambridge (GB)
- Shanghai Jiao Tong University (CN)
- University of Virginia (US)
- Breakthrough T1D (US)
- Joslin Diabetes Center (US)
- Endocrinology Research Center (RU)
- KU Leuven (BE)
- University of East Anglia (GB)
- Schneider Children's Medical Center (IL)
- Steno Diabetes Center Copenhagen (DK)
- CGParkin Communications, Inc., Henderson, NV
- Department of Endocrinology, Diabetes, and Nutrition, Montpellier University Hospital; Institute of Functional Genomics, University of Montpellier; and INSERM Clinical Investigation Centre, Montpellier, France
- Biomedical Informatics Consultants LLC, Potomac, MD
- DiaCare, Ahmedabad, Gujarat, India
- University of Florida (US)
- dQ&A Market Research, Inc., San Francisco, CA
- Nihon University (JP)
- Yale University (US)
- Tel Aviv University (IL)
- Corresponding author
- Battelino, Tadej
- ORCID
- Battelino, Tadej
- Danne, Thomas
- Bergenstal, Richard M.
- Amiel, Stephanie A.
- Beck, Roy
- Biester, Torben
- Bosi, Emanuele
- Buckingham, Bruce A.
- Cefalu, William T.
- Close, Kelly L.
- Cobelli, Claudio
- Dassau, Eyal
- DeVries, J. Hans
- Donaghue, Kim C.
- Doyle, Francis J.
- Garg, Satish
- Grunberger, George
- Heller, Simon
- Heinemann, Lutz
- Hirsch, Irl B.
- Hovorka, Roman
- Jia, Weiping
- Kordonouri, Olga
- Kovatchev, Boris
- Kowalski, Aaron
- Laffel, Lori
- Levine, Brian
- Mayorov, Alexander
- Mathieu, Chantal
- Murphy, Helen R.
- Nimri, Revital
- Nørgaard, Kirsten
- Parkin, Christopher G.
- Renard, Eric
- Rodbard, David
- Saboo, Banshi
- Schatz, Desmond
- Stoner, Keaton
- Urakami, Tatsuiko
- Weinzimer, Stuart A.
- Phillip, Moshe
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-08
- Volume
- 42
- Issue
- 8
- Pages
- 1593-1603
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6973648
- OpenAlex
- W2948261890
- Cited by
- 4,237
- References
- 96
- Citations by year
- 2026: 716 · 2025: 649 · 2024: 655 · 2023: 575 · 2022: 619 · 2021: 556 · 2020: 398 · 2019: 61
- FWCI
- 215.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Lirias (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust
- University of Virginia
- Insulet Corporation
- MannKind Corporation
- Dexcom
- OPKO Health
- Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
- National Institute for Health and Care Research (NF-SI-0515-10079, CDF-2013-06-035, 16/35/01)
- Universiteit van Amsterdam
- KU Leuven
- Novo Nordisk
- Roche Diabetes Care
- National Institutes of Health (UL1TR001863)
- U.S. Food and Drug Administration
- Abbott Diabetes Care
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- continuous glucose monitoring, time in range, glycemic targets, diabetes management, clinical guidelines
- MeSH terms
- Data Accuracy, Blood Glucose, Data Interpretation, Statistical, Diabetes Mellitus, Glycated Hemoglobin, Humans, Patient Care Planning, Reference Values, Time Factors, Blood Glucose Self-Monitoring, Practice Guidelines as Topic, Internationality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.